Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis

—Topline Data Remains on Track to be Reported in Q2 of 2024—

—More than 1,700 Adult Patients Enrolled in Global, Registrational Study of First-in-Class Treatment Candidate—

Read more at prnewswire.com